Get the Stockscreener App
4.40
0.56%
-0.025
After Hours:
4.40
Marker Therapeutics Inc stock is currently priced at $4.40, with a 24-hour trading volume of 9,980.
It has seen a -0.56% decreased in the last 24 hours and a -10.39% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.35 pivot point. If it approaches the $4.56 resistance level, significant changes may occur.
Previous Close:
$4.425
Open:
$4.5
24h Volume:
9,980
Market Cap:
$39.17M
Revenue:
-
Net Income/Loss:
$-9.29M
P/E Ratio:
-2.8205
EPS:
-1.56
Net Cash Flow:
$-20.38M
1W Performance:
+2.09%
1M Performance:
-10.39%
6M Performance:
+57.14%
1Y Performance:
+378.26%
1D Range:
$4.36
$4.59
52W Range:
$0.76
$9.6799
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
713 400 6400
Address
3200 Southwest Freeway, Suite 2500, Houston, TX
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
GlobeNewswire Inc.
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
GlobeNewswire Inc.
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewswire Inc.
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
GlobeNewswire Inc.
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
GlobeNewswire Inc.
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
GlobeNewswire Inc.
Marker Therapeutics Inc Stock (MRKR) Financials Data
Marker Therapeutics Inc (MRKR) Net Income 2024
MRKR net income (TTM) was -$9.29 million for the quarter ending September 30, 2023, a +74.08% increase year-over-year.
Marker Therapeutics Inc (MRKR) Cash Flow 2024
MRKR recorded a free cash flow (TTM) of -$20.38 million for the quarter ending September 30, 2023, a +21.24% increase year-over-year.
Marker Therapeutics Inc (MRKR) Earnings per Share 2024
MRKR earnings per share (TTM) was -$1.07 for the quarter ending September 30, 2023, a +75.12% growth year-over-year.
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
3.69%
0.93%
Cap:
|
Volume (24h):